Glycine metabolomic changes induced by anticancer agents in A549 cells

Guo, Kaiqiang; Cao, Yin; Li, Zan; Zhou, Xiaoxiao; Ding, Rong; Chen, Kejing; Liu, Yan; Qiu, Ying-Kun; Wu, Zhixian; Fang, Meijuan

doi:10.1007/s00726-020-02853-0

Cited by 8 publications

(7 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin/tamoxifen significantly reduced the level of phosphocholine in human breast cancer cells [ 22 ]. Anticancer drugs including cisplatin changed the glycine metabolism of lung cancer cells, which was characterized by inhibiting pyruvate metabolism and down-regulating betaine aldehyde and 5′-phosphoribosylglycinamide [ 23 ]. Metabolomics profiling revealed that when three-negative breast cancer (TNBC) cells were exposed to cisplatin and doxorubicin, their metabolites of arginine and polyamine were changed [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…The cells were cultured at 37 °C in a 5% CO 2 incubator for 48 h. The medium was replaced with 100 μL fresh DMEM containing 10 μL CCK8 solution (MedChemExpress, Monmouth Junction, NJ, USA), and cells were incubated at 37 °C for 2 h. Absorbance at 450 nm was measured by a microplate reader (Promega, Madison, WI, USA). The cell viability and the IC 50 (50% growth inhibitory concentration) were determined according to the readings of the treated wells and the control wells (absence of test compound) with correction of background absorbance [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure

Chen

Kuang

et al. 2022

Metabolites

View full text Add to dashboard Cite

Metabolic reprogramming is one of the hallmarks of a tumor. It not only promotes the development and progression of tumor but also contributes to the resistance of tumor cells to chemotherapeutics. The difference in the metabolism between drug-resistant and sensitive tumor cells indicates that drug-resistant tumor cells have experienced metabolic adaptation. The metabolic response induced by chemotherapy is dynamic, but the early metabolic response of tumor cells to anticancer drugs and the effect of an initial response on the development of drug resistance have not been well studied. Early metabolic intervention may prevent or slow down the development of drug resistance. The differential metabolic responses of normal cells and tumor cells to drugs are unclear. The specific metabolites or metabolic pathways of tumor cells to chemotherapeutic drugs can be used as the target of metabolic intervention in tumor therapy. In this study, we used comparative metabolomics to analyze the differential metabolic responses of oral cancer cells and normal oral epithelial cells to short-term cisplatin exposure, and to identify the marker metabolites of early response in oral cancer cells. Oral cancer cells showed a dynamic metabolic response to cisplatin. Seven and five metabolites were identified as specific response markers to cisplatin exposure in oral cancer cell SCC-9 and normal oral epithelial cell HOEC, respectively. Glyoxylate and dicarboxylate metabolism and fructose, malate, serine, alanine, sorbose and glutamate were considered as specific enriched metabolic pathways and biomarkers of SCC-9 cells in response to cisplatin, respectively. The existence of differential metabolic responses lays a foundation for tumor chemotherapy combined with metabolic intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure

Chen

Kuang

et al. 2022

Metabolites

View full text Add to dashboard Cite

show abstract

“…According to the report of Hu and coworkers, glycodeoxycholic acid and glycocholic acid might be potential biomarkers for the efficacy of anlotinib, and both of them are associated with glycine. 31 Guo et al found that after treatment with afatinib, gefitinib and Targretin, the metabolism of glycine, serine and threonine was significantly disturbed, 32 suggesting that this metabolic pathway might be relevant to the underlying mechanism of many antitumor agents. In our study, anlotinib also affected glycine, serine and threonine metabolism, which further supports this point.…”

Section: Discussionmentioning

confidence: 99%

A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib

Pan¹,

Chen²,

Nie³

et al. 2021

CMAR

View full text Add to dashboard Cite

Background Anlotinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor recommended for the treatment of advanced lung cancer patients after at least two previous systemic chemotherapies. Currently, many patients with lung cancer do not respond well to anlotinib treatment. Therefore, the aim of this metabolomic study was to determine the internal mechanism of anlotinib action at the molecular level and to identify the potential biomarkers and pathways associated with the therapeutic effects of anlotinib. Methods A total of 20 male nude mice were randomly divided into 2 groups and treated with anlotinib or physiological saline. Ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry was performed to analyze the serum samples and determine the differential metabolites and pathways between anlotinib and control groups. Results We observed significant differences between the anlotinib and control groups, and 13 endogenous differential metabolites and 5 potential metabolic pathways were identified. Glyoxylate and dicarboxylate metabolism, tryptophan metabolism, glycine, serine and threonine metabolism, phenylalanine metabolism and valine, leucine and isoleucine biosynthesis were the most important pathways regulated by anlotinib in vivo. Notably, these 5 differential pathways were highly associated with the TCA cycle, which is important in the proliferation and apoptosis of cancer cells. Conclusion This serum metabolomic study revealed distinct metabolic profiles in lung cancer-bearing mice treated with anlotinib and identified differential metabolites and pathways between the anlotinib and control groups, which may provide new ideas for the clinical application of anlotinib.

show abstract

“…Glycine, the simplest natural amino acid, is involved in various metabolic and pathophysiological processes important in the growth and survival of proliferating cells, including cancer cells [21][22][23]. Thus, the glycine-related pathways represent an attractive target for the development of anticancer therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis

et al. 2021

View full text Add to dashboard Cite

Despite multimodal treatment strategies, clinical outcomes of advanced stage colorectal cancer (CRC) patients remain poor. Neoadjuvant/adjuvant chemotherapy efficacy is limited due to chemoresistance, toxicity, and negative side effects. Since both melatonin and glycine have anti-cancer activities without relevant side effects, this study was designed to investigate their combined effects in experimental CRC liver metastases. CRC metastasis with CC531 cells were induced in male Wistar rats. Melatonin and glycine alone or their combination were supplemented for 14 days (n = 100). Blood parameters, a micro-computed tomography scan (tumor volume over time), and immunohistochemistry for Ki67 and CD31 expression in tumor tissue were compared between groups. Melatonin and glycine alone significantly reduced the tumor volume by 63.2% (p = 0.002) and 43% (p = 0.044) over time, respectively, while tumor volume increased by 8.7% in the controls. Moreover, treatment with melatonin and glycine alone reduced the tumor proliferation index. Most interestingly, the combination therapy did not have any influence on the above-mentioned tumor parameters. The leukocyte count was significantly increased with melatonin at the end of the experiment (p = 0.012) which was due to a high lymphocytes count. Tumor microvascular density was significantly reduced in all treatment groups. The results of this study suggest an inhibitory function for melatonin and glycine alone in the case of CRC liver metastasis growth by acting as natural antiangiogenic molecules, followed by angiogenesis-dependent cancer proliferation and immunomodulation.

show abstract

Glycine metabolomic changes induced by anticancer agents in A549 cells

Cited by 8 publications

References 63 publications

The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure

The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure

A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib

Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis

Contact Info

Product

Resources

About